Potassium channel blocker

Last updated
Tetraethylammonium is a commonly used potassium channel blocker Tetraethylammonium.svg
Tetraethylammonium is a commonly used potassium channel blocker

Potassium channel blockers are agents which interfere with conduction through potassium channels.

Contents

Medical uses

Arrhythmia

Effect of class III antiarrhythmic agent on cardiac action potential. Action potential Class III.svg
Effect of class III antiarrhythmic agent on cardiac action potential.

Potassium channel blockers used in the treatment of cardiac arrhythmia are classified as class III antiarrhythmic agents.

Mechanism

Class III agents predominantly block the potassium channels, thereby prolonging repolarization. [1] More specifically, their primary effect is on IKr. [2]

Since these agents do not affect the sodium channel, conduction velocity is not decreased. The prolongation of the action potential duration and refractory period, combined with the maintenance of normal conduction velocity, prevent re-entrant arrhythmias. (The re-entrant rhythm is less likely to interact with tissue that has become refractory).

Examples and uses

  • Amiodarone is indicated for the treatment of refractory VT or VF, particularly in the setting of acute ischemia. Amiodarone is also safe to use in individuals with cardiomyopathy and atrial fibrillation, to maintain normal sinus rhythm. Amiodarone prolongation of the action potential is uniform over a wide range of heart rates, so this drug does not have reverse use-dependent action. Amiodarone was the first agent described in this class. [3] Amiodarone should only be used to treat adults with life-threatening ventricular arrhythmias when other treatments are ineffective or have not been tolerated. [4]
  • Dofetilide blocks only the rapid K channels; this means that at higher heart rates, when there is increased involvement of the slow K channels, dofetilide has less of an action potential-prolonging effect.
  • Sotalol is indicated for the treatment of atrial or ventricular tachyarrhythmias, and AV re-entrant arrhythmias.
  • Ibutilide is the only antiarrhythmic agent currently approved by the Food and Drug Administration for acute conversion of atrial fibrillation to sinus rhythm.
  • Azimilide
  • Bretylium
  • Clofilium
  • E-4031
  • Nifekalant [5]
  • Tedisamil
  • Sematilide

Side effects

These agents include a risk of torsades de pointes. [6]

Anti-diabetics

Sulfonylureas, such as gliclazide, are ATP-sensitive potassium channel blockers.

Other uses

Dalfampridine, A potassium channel blocker has also been approved for use in the treatment of multiple sclerosis. [7]

A study appears to indicate that topical spray of a selective Tandem pore Acid-Sensitive K+ (TASK 1/3 K+) (potassium antagonist) increases upper airway dilator muscle activity and reduces pharyngeal collapsibility during anesthesia and obstructive sleep apnoea (OSA). [8] [9]

Reverse use dependence

Potassium channel blockers exhibit reverse use-dependent prolongation of the action potential duration. Reverse use dependence is the effect where the efficacy of the drug is reduced after repeated use of the tissue. [10] This contrasts with (ordinary) use dependence, where the efficacy of the drug is increased after repeated use of the tissue.

Reverse use dependence is relevant for potassium channel blockers used as class III antiarrhythmics. Reverse use dependent drugs that slow heart rate (such as quinidine) can be less effective at high heart rates. [10] The refractoriness of the ventricular myocyte increases at lower heart rates.[ citation needed ] This increases the susceptibility of the myocardium to early Afterdepolarizations (EADs) at low heart rates.[ citation needed ] Antiarrhythmic agents that exhibit reverse use-dependence (such as quinidine) are more efficacious at preventing a tachyarrhythmia than converting someone into normal sinus rhythm.[ citation needed ] Because of the reverse use-dependence of class III agents, at low heart rates class III antiarrhythmic agents may paradoxically be more arrhythmogenic.

Drugs such as quinidine may be both reverse use dependent and use dependent. [10]

Calcium-activated potassium channel blockers

Examples of calcium-activated potassium channel blockers include:

Inwardly rectifying channel blockers

Examples of inwardly rectifying channel blockers include:

ROMK (Kir1.1)

Nonselective: Ba2+, [22] Cs+ [23]

GPCR regulated (Kir3.x)

ATP-sensitive (Kir6.x)

Tandem pore domain channel blockers

Examples of tandem pore domain channel blockers include:

Voltage-gated channel blockers

Examples of voltage-gated channel blockers include:

hERG (KCNH2, Kv11.1)-specific

KCNQ (Kv7)-specific

See also

Notes

  1. ↑ Amiodarone also blocks CACNA2D2-containing voltage gated calcium channels
  2. ↑ works by selectively blocking the rapid component of the delayed rectifier outward potassium current (IKr)
  3. ↑ blocks potassium channels of the hERG-type
  4. ↑ Primarily inhibits outward voltage-gated Kv2.1 potassium channel currents.
  5. ↑ a very potent inhibitor of the rat Kv1.3 voltage-gated potassium channel

Related Research Articles

Antiarrhythmic agents, also known as cardiac dysrhythmia medications, are a class of drugs that are used to suppress abnormally fast rhythms (tachycardias), such as atrial fibrillation, supraventricular tachycardia and ventricular tachycardia.

<span class="mw-page-title-main">Dofetilide</span> Antiarrhythmic medication

Dofetilide is a class III antiarrhythmic agent. It is marketed under the trade name Tikosyn by Pfizer, and is available in the United States in capsules containing 125, 250, and 500 µg of dofetilide. It is not available in Europe or Australia.

<span class="mw-page-title-main">Quinidine</span> Antiarrythmic medication

Quinidine is a class IA antiarrhythmic agent used to treat heart rhythm disturbances. It is a diastereomer of antimalarial agent quinine, originally derived from the bark of the cinchona tree. The drug causes increased action potential duration, as well as a prolonged QT interval. As of 2019, its IV formulation is no longer being manufactured for use in the United States.

<span class="mw-page-title-main">Amiodarone</span> Antiarrhythmic medication used for various types of irregular heartbeats

Amiodarone is an antiarrhythmic medication used to treat and prevent a number of types of cardiac dysrhythmias. This includes ventricular tachycardia (VT), ventricular fibrillation (VF), and wide complex tachycardia, as well as atrial fibrillation and paroxysmal supraventricular tachycardia. Evidence in cardiac arrest, however, is poor. It can be given by mouth, intravenously, or intraosseously. When used by mouth, it can take a few weeks for effects to begin.

<span class="mw-page-title-main">Torsades de pointes</span> Type of abnormal heart rhythm

Torsades de pointes, torsade de pointes or torsades des pointes is a specific type of abnormal heart rhythm that can lead to sudden cardiac death. It is a polymorphic ventricular tachycardia that exhibits distinct characteristics on the electrocardiogram (ECG). It was described by French physician François Dessertenne in 1966. Prolongation of the QT interval can increase a person's risk of developing this abnormal heart rhythm, occurring in between 1% and 10% of patients who receive QT-prolonging antiarrhythmic drugs.

<span class="mw-page-title-main">Flecainide</span> Antiarrhythmic medication

Flecainide is a medication used to prevent and treat abnormally fast heart rates. This includes ventricular and supraventricular tachycardias. Its use is only recommended in those with dangerous arrhythmias or when significant symptoms cannot be managed with other treatments. Its use does not decrease a person's risk of death. It is taken by mouth or injection into a vein.

<span class="mw-page-title-main">Potassium channel</span> Ion channel that selectively passes K+

Potassium channels are the most widely distributed type of ion channel found in virtually all organisms. They form potassium-selective pores that span cell membranes. Potassium channels are found in most cell types and control a wide variety of cell functions.

<span class="mw-page-title-main">Procainamide</span> Medication to treat cardiac arrhythmias

Procainamide (PCA) is a medication of the antiarrhythmic class used for the treatment of cardiac arrhythmias. It is a sodium channel blocker of cardiomyocytes; thus it is classified by the Vaughan Williams classification system as class Ia. In addition to blocking the INa current, it inhibits the IKr rectifier K+ current. Procainamide is also known to induce a voltage-dependent open channel block on the batrachotoxin (BTX)-activated sodium channels in cardiomyocytes.

hERG Mammalian protein found in humans

hERG is a gene that codes for a protein known as Kv11.1, the alpha subunit of a potassium ion channel. This ion channel is best known for its contribution to the electrical activity of the heart: the hERG channel mediates the repolarizing IKr current in the cardiac action potential, which helps coordinate the heart's beating.

<span class="mw-page-title-main">Azimilide</span> Chemical compound

Azimilide is a class ΙΙΙ antiarrhythmic drug. The agents from this heterogeneous group have an effect on the repolarization, they prolong the duration of the action potential and the refractory period. Also they slow down the spontaneous discharge frequency of automatic pacemakers by depressing the slope of diastolic depolarization. They shift the threshold towards zero or hyperpolarize the membrane potential. Although each agent has its own properties and will have thus a different function.

<span class="mw-page-title-main">Prajmaline</span> Chemical compound

Prajmaline (Neo-gilurythmal) is a class Ia antiarrhythmic agent which has been available since the 1970s. Class Ia drugs increase the time one action potential lasts in the heart. Prajmaline is a semi-synthetic propyl derivative of ajmaline, with a higher bioavailability than its predecessor. It acts to stop arrhythmias of the heart through a frequency-dependent block of cardiac sodium channels.

<span class="mw-page-title-main">Dronedarone</span> Medication

Dronedarone, sold under the brand name Multaq, is a class III antiarrhythmic medication developed by Sanofi-Aventis. It was approved by the US Food and Drug Administration (FDA) in July 2009. Besides being indicated in arrhythmias, it was recommended as an alternative to amiodarone for the treatment of atrial fibrillation and atrial flutter in people whose hearts have either returned to normal rhythm or who undergo drug therapy or electric shock treatment i.e. direct current cardioversion (DCCV) to maintain normal rhythm. It is a class III antiarrhythmic drug. The FDA label includes a claim for reducing hospitalization, but not for reducing mortality, as a reduction in mortality was not demonstrated in the clinical development program. A trial of the drug in heart failure was stopped as an interim analysis showed a possible increase in heart failure deaths, in people with moderate to severe congestive heart failure.

<span class="mw-page-title-main">Pilsicainide</span> Chemical compound

Pilsicainide (INN) is an antiarrhythmic agent. It is marketed in Japan as サンリズム (Sunrythm). It was developed by Suntory Holdings Limited and first released in 1991. The JAN applies to the hydrochloride salt, pilsicainide hydrochloride.

Sodium channel blockers are drugs which impair the conduction of sodium ions (Na+) through sodium channels.

<span class="mw-page-title-main">E-4031</span> Chemical compound

E-4031 is an experimental class III antiarrhythmic drug that blocks potassium channels of the hERG-type.

<span class="mw-page-title-main">BRL-32872</span> Chemical compound

BRL-32872 is an experimental drug candidate that provides a novel approach to the treatment of cardiac arrhythmia. Being a derivative of verapamil, it possesses the ability to inhibit Ca+2 membrane channels. Specific modifications in hydrogen bonding activity, nitrogen lone pair availability, and molecular flexibility allow BRL-32872 to inhibit K+ channels as well. As such, BRL-32872 is classified as both a class III (K+ blocking) and class IV (Ca+2 blocking) antiarrhythmic agent.

<span class="mw-page-title-main">Celivarone</span> Experimental drug being tested for use in pharmacological antiarrhythmic therapy

Celivarone is an experimental drug being tested for use in pharmacological antiarrhythmic therapy. Cardiac arrhythmia is any abnormality in the electrical activity of the heart. Arrhythmias range from mild to severe, sometimes causing symptoms like palpitations, dizziness, fainting, and even death. They can manifest as slow (bradycardia) or fast (tachycardia) heart rate, and may have a regular or irregular rhythm.

<span class="mw-page-title-main">Budiodarone</span> Chemical compound

Budiodarone (ATI-2042) is an antiarrhythmic agent and chemical analog of amiodarone that is currently being studied in clinical trials. Amiodarone is considered the most effective antiarrhythmic drug available, but its adverse side effects, including hepatic, pulmonary and thyroid toxicity as well as multiple drug interactions, are discouraging its use. Budiodarone only differs in structure from amiodarone through the presence of a sec-butyl acetate side chain at position 2 of the benzofuran moiety. This side chain allows for budiodarone to have a shorter half-life in the body than amiodarone which allows it to have a faster onset of action and metabolism while still maintaining similar electrophysiological activity. The faster metabolism of budiodarone allows for fewer adverse side effects than amiodarone principally due to decreased levels of toxicity in the body.

<span class="mw-page-title-main">AZD1305</span> Chemical compound

AZD1305 is an experimental drug candidate that is under investigation for the management and reversal of cardiac arrhythmias, specifically atrial fibrillation and flutter. In vitro studies have shown that this combined-ion channel blocker inhibits rapidly the activating delayed-rectifier potassium current (IKr), L-type calcium current, and inward sodium current (INa).

QT prolongation is a measure of delayed ventricular repolarisation, which means the heart muscle takes longer than normal to recharge between beats. It is an electrical disturbance which can be seen on an electrocardiogram (ECG). Excessive QT prolongation can trigger tachycardias such as torsades de pointes (TdP). QT prolongation is an established side effect of antiarrhythmics, but can also be caused by a wide range of non-cardiac medicines, including antibiotics, antidepressants, antihistamines, opioids, and complementary medicines. On an ECG, the QT interval represents the summation of action potentials in cardiac muscle cells, which can be caused by an increase in inward current through sodium or calcium channels, or a decrease in outward current through potassium channels. By binding to and inhibiting the “rapid” delayed rectifier potassium current protein, certain drugs are able to decrease the outward flow of potassium ions and extend the length of phase 3 myocardial repolarization, resulting in QT prolongation.

References

  1. ↑ Lenz TL, Hilleman DE (July 2000). "Dofetilide, a new class III antiarrhythmic agent". Pharmacotherapy. 20 (7): 776–86. doi:10.1592/phco.20.9.776.35208. PMID   10907968. S2CID   19897963.
  2. ↑ Riera AR, Uchida AH, Ferreira C, et al. (2008). "Relationship among amiodarone, new class III antiarrhythmics, miscellaneous agents and acquired long QT syndrome". Cardiol J. 15 (3): 209–19. PMID   18651412.
  3. ↑ "Milestones in the Evolution of the Study of Arrhythmias".
  4. ↑ "FDA MedWatch". Food and Drug Administration .
  5. ↑ Sahara M, Sagara K, Yamashita T, Iinuma H, Fu LT, Watanabe H (August 2003). "Nifekalant hydrochloride, a novel class III antiarrhythmic agent, suppressed postoperative recurrent ventricular tachycardia in a patient undergoing coronary artery bypass grafting and the Dor approach". Circ. J. 67 (8): 712–4. doi: 10.1253/circj.67.712 . PMID   12890916. S2CID   44536952.
  6. ↑ "Introduction: Arrhythmias and Conduction Disorders: Merck Manual Professional".
  7. ↑ Judge SI, Bever CT (July 2006). "Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment". Pharmacol. Ther. 111 (1): 224–59. doi:10.1016/j.pharmthera.2005.10.006. PMID   16472864.
  8. ↑ Flinders unu,UA:Sleep apnea solution could be right under your nose
  9. ↑ NIH PubMed:TASK channels: channelopathies, trafficking, and receptor-mediated inhibition
  10. 1 2 3 Hondeghem, L. M. (1995), Breithardt, Günter; Borggrefe, Martin; Camm, A. John; Shenasa, Mohammad (eds.), "Use Dependence and Reverse Use Dependence of Antiarrhythmic Agents: Pro- and Antiarrhythmic Actions", Antiarrhythmic Drugs: Mechanisms of Antiarrhythmic and Proarrhythmic Actions, Springer Berlin Heidelberg, pp. 92–105, doi:10.1007/978-3-642-85624-2_6, ISBN   9783642856242
  11. ↑ Thompson J, Begenisich T (May 2000). "Electrostatic interaction between charybdotoxin and a tetrameric mutant of Shaker K(+) channels". Biophysical Journal. 78 (5): 2382–91. Bibcode:2000BpJ....78.2382T. doi:10.1016/S0006-3495(00)76782-8. PMC   1300827 . PMID   10777734.
  12. ↑ Naranjo D, Miller C (January 1996). "A strongly interacting pair of residues on the contact surface of charybdotoxin and a Shaker K+ channel". Neuron. 16 (1): 123–30. doi: 10.1016/S0896-6273(00)80029-X . PMID   8562075. S2CID   16794677.
  13. ↑ Yu M, Liu SL, Sun PB, Pan H, Tian CL, Zhang LH (January 2016). "Peptide toxins and small-molecule blockers of BK channels". Acta Pharmacologica Sinica. 37 (1): 56–66. doi:10.1038/aps.2015.139. PMC   4722972 . PMID   26725735.
  14. 1 2 3 4 5 Rang, HP (2015). Pharmacology (8 ed.). Edinburgh: Churchill Livingstone. p. 59. ISBN   978-0-443-07145-4.
  15. ↑ Candia, S; Garcia, ML; Latorre, R (1992). "Mode of action of iberiotoxin, a potent blocker of the large conductance Ca(2+)-activated K+ channel". Biophysical Journal. 63 (2): 583–90. Bibcode:1992BpJ....63..583C. doi:10.1016/S0006-3495(92)81630-2. PMC   1262182 . PMID   1384740.
  16. ↑ M. Stocker; M. Krause; P. Pedarzani (1999). "An apamin-sentisitive Ca2+-activated K+ current in hippocampal pyramidal neurons". PNAS. 96 (8): 4662–4667. Bibcode:1999PNAS...96.4662S. doi: 10.1073/pnas.96.8.4662 . PMC   16389 . PMID   10200319.
  17. ↑ Baldus, Marc; Becker, Stefan; Pongs, Olaf; Martin-Eauclaire, Marie-France; Hornig, Sönke; Giller, Karin; Lange, Adam (April 2006). "Toxin-induced conformational changes in a potassium channel revealed by solid-state NMR". Nature. 440 (7086): 959–962. Bibcode:2006Natur.440..959L. doi:10.1038/nature04649. ISSN   1476-4687. PMID   16612389. S2CID   4429604.
  18. ↑ Martin-Eauclaire, M. F.; Mansuelle, P.; Rochat, H.; Benslimane, A.; Zerrouk, H.; Gola, M.; Jacquet, G.; Crest, M. (1992-01-25). "Kaliotoxin, a novel peptidyl inhibitor of neuronal BK-type Ca(2+)-activated K+ channels characterized from Androctonus mauretanicus mauretanicus venom". Journal of Biological Chemistry. 267 (3): 1640–1647. doi: 10.1016/S0021-9258(18)45993-5 . ISSN   0021-9258. PMID   1730708.
  19. ↑ Philippe, G (15 February 2016). "Lolitrem B and Indole Diterpene Alkaloids Produced by Endophytic Fungi of the Genus Epichloë and Their Toxic Effects in Livestock". Toxins. 8 (2): 47. doi: 10.3390/toxins8020047 . PMC   4773800 . PMID   26891327.
  20. ↑ McLeod, JF; Leempoels, JM; Peng, SX; Dax, SL; Myers, LJ; Golder, FJ (November 2014). "GAL-021, a new intravenous BKCa-channel blocker, is well tolerated and stimulates ventilation in healthy volunteers". British Journal of Anaesthesia. 113 (5): 875–83. doi: 10.1093/bja/aeu182 . PMID   24989775.
  21. ↑ Dopico AM, Bukiya AN, Kuntamallappanavar G, Liu J (2016). "Modulation of BK Channels by Ethanol". International Review of Neurobiology. 128: 239–79. doi:10.1016/bs.irn.2016.03.019. ISBN   9780128036198. PMC   5257281 . PMID   27238266.
  22. 1 2 Patnaik, Pradyot (2003). Handbook of inorganic chemicals. McGraw-Hill. pp.  77–78. ISBN   978-0-07-049439-8.
  23. ↑ Sackin, H; Syn, S; Palmer, L G; Choe, H; Walters, D E (Feb 2001). "Regulation of ROMK by extracellular cations". Biophysical Journal. 80 (2): 683–697. Bibcode:2001BpJ....80..683S. doi:10.1016/S0006-3495(01)76048-1. ISSN   0006-3495. PMC   1301267 . PMID   11159436.
  24. ↑ Kobayashi T, Washiyama K, Ikeda K (March 2006). "Inhibition of G protein-activated inwardly rectifying K+ channels by ifenprodil". Neuropsychopharmacology. 31 (3): 516–24. doi: 10.1038/sj.npp.1300844 . PMID   16123769. S2CID   10093765.
  25. ↑ Soeda, Fumio; Fujieda, Yoshiko; Kinoshita, Mizue; Shirasaki, Tetsuya; Takahama, Kazuo (2016). "Centrally acting non-narcotic antitussives prevent hyperactivity in mice: Involvement of GIRK channels". Pharmacology Biochemistry and Behavior. 144: 26–32. doi:10.1016/j.pbb.2016.02.006. ISSN   0091-3057. PMID   26892760. S2CID   30118634.
  26. ↑ YAMAMOTO, Gen; SOEDA, Fumio; SHIRASAKI, Tetsuya; TAKAHAMA, Kazuo (2011). "Is the GIRK Channel a Possible Target in the Development of a Novel Therapeutic Drug of Urinary Disturbance?". Yakugaku Zasshi. 131 (4): 523–532. doi: 10.1248/yakushi.131.523 . ISSN   0031-6903. PMID   21467791.
  27. ↑ KAWAURA, Kazuaki; HONDA, Sokichi; SOEDA, Fumio; SHIRASAKI, Tetsuya; TAKAHAMA, Kazuo (2010). "A Novel Antidepressant-like Action of Drugs Possessing GIRK Channel Blocking Action in Rats". Yakugaku Zasshi. 130 (5): 699–705. doi: 10.1248/yakushi.130.699 . ISSN   0031-6903. PMID   20460867.
  28. ↑ Jin, W; Lu, Z (1998). "A novel high affinity inhibitor for inward-rectifier K+ channels". Biochemistry. 37 (38): 13291–13299. doi:10.1021/bi981178p. PMID   9748337.
  29. ↑ Kawaura, Kazuaki; Ogata, Yukino; Inoue, Masako; Honda, Sokichi; Soeda, Fumio; Shirasaki, Tetsuya; Takahama, Kazuo (2009). "The centrally acting non-narcotic antitussive tipepidine produces antidepressant-like effect in the forced swimming test in rats" (PDF). Behavioural Brain Research. 205 (1): 315–318. doi:10.1016/j.bbr.2009.07.004. ISSN   0166-4328. PMID   19616036. S2CID   29236491.
  30. ↑ Hannan SB, Penzinger R, Mikute G, Smart TG (July 2023). "CGP7930 - An allosteric modulator of GABABRs, GABAARs and inwardly-rectifying potassium channels". Neuropharmacology. 109644. doi: 10.1016/j.neuropharm.2023.109644 . PMID   37422181.
  31. ↑ Lawrence, C. L.; Proks, P.; Rodrigo, G. C.; Jones, P.; Hayabuchi, Y.; Standen, N. B.; Ashcroft, F. M. (2001). "Gliclazide produces high-affinity block of K ATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells". Diabetologia. 44 (8): 1019–25. doi: 10.1007/s001250100595 . PMID   11484080. S2CID   12635381.
  32. ↑ Serrano-Martín X, Payares G, Mendoza-León A (December 2006). "Glibenclamide, a blocker of K+(ATP) channels, shows antileishmanial activity in experimental murine cutaneous leishmaniasis". Antimicrob. Agents Chemother. 50 (12): 4214–6. doi:10.1128/AAC.00617-06. PMC   1693980 . PMID   17015627.
  33. ↑ Kindler CH, Yost CS, Gray AT (Apr 1999). "Local anesthetic inhibition of baseline potassium channels with two pore domains in tandem". Anesthesiology. 90 (4): 1092–102. doi: 10.1097/00000542-199904000-00024 . PMID   10201682.
  34. 1 2 Meadows HJ, Randall AD (Mar 2001). "Functional characterisation of human TASK-3, an acid-sensitive two-pore domain potassium channel". Neuropharmacology. 40 (4): 551–9. doi:10.1016/S0028-3908(00)00189-1. PMID   11249964. S2CID   20181576.
  35. ↑ Kindler CH, Paul M, Zou H, Liu C, Winegar BD, Gray AT, Yost CS (Jul 2003). "Amide local anesthetics potently inhibit the human tandem pore domain background K+ channel TASK-2 (KCNK5)". The Journal of Pharmacology and Experimental Therapeutics. 306 (1): 84–92. doi:10.1124/jpet.103.049809. PMID   12660311. S2CID   1621972.
  36. ↑ Punke MA, Licher T, Pongs O, Friederich P (Jun 2003). "Inhibition of human TREK-1 channels by bupivacaine". Anesthesia and Analgesia. 96 (6): 1665–73. doi: 10.1213/01.ANE.0000062524.90936.1F . PMID   12760993. S2CID   39630495.
  37. ↑ Lesage F, Guillemare E, Fink M, Duprat F, Lazdunski M, Romey G, Barhanin J (Mar 1996). "TWIK-1, a ubiquitous human weakly inward rectifying K+ channel with a novel structure". The EMBO Journal. 15 (5): 1004–11. doi:10.1002/j.1460-2075.1996.tb00437.x. PMC   449995 . PMID   8605869.
  38. ↑ Duprat F, Lesage F, Fink M, Reyes R, Heurteaux C, Lazdunski M (Sep 1997). "TASK, a human background K+ channel to sense external pH variations near physiological pH". The EMBO Journal. 16 (17): 5464–71. doi:10.1093/emboj/16.17.5464. PMC   1170177 . PMID   9312005.
  39. ↑ Reyes R, Duprat F, Lesage F, Fink M, Salinas M, Farman N, Lazdunski M (Nov 1998). "Cloning and expression of a novel pH-sensitive two pore domain K+ channel from human kidney". The Journal of Biological Chemistry. 273 (47): 30863–9. doi: 10.1074/jbc.273.47.30863 . PMID   9812978. S2CID   20414039.
  40. ↑ Meadows HJ, Benham CD, Cairns W, Gloger I, Jennings C, Medhurst AD, Murdock P, Chapman CG (Apr 2000). "Cloning, localisation and functional expression of the human orthologue of the TREK-1 potassium channel". Pflügers Archiv. 439 (6): 714–22. doi:10.1007/s004240050997. PMID   10784345.
  41. 1 2 Kennard (2005). "Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine". British Journal of Pharmacology. 144 (6): 821–9. doi:10.1038/sj.bjp.0706068. PMC   1576064 . PMID   15685212.
  42. ↑ "UniProtKB - Q9NPC2 (KCNK9_HUMAN)". Uniprot . Retrieved 2019-05-29.
  43. ↑ Kirsch GE, Narahashi T (June 1978). "3,4-diaminopyridine. A potent new potassium channel blocker". Biophys J. 22 (3): 507–12. Bibcode:1978BpJ....22..507K. doi:10.1016/s0006-3495(78)85503-9. PMC   1473482 . PMID   667299.
  44. ↑ Judge S, Bever C (2006). "Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment". Pharmacol. Ther. 111 (1): 224–59. doi:10.1016/j.pharmthera.2005.10.006. PMID   16472864.
  45. ↑ "Amiodarone". Drugbank. Retrieved 2019-05-28.
  46. 1 2 Wang, Shao-Ping; Wang, Jian-An; Luo, Rong-Hua; Cui, Wen-Yu; Wang, Hai (September 2008). "Potassium channel currents in rat mesenchymal stem cells and their possible roles in cell proliferation". Clinical and Experimental Pharmacology & Physiology. 35 (9): 1077–1084. doi:10.1111/j.1440-1681.2008.04964.x. ISSN   1440-1681. PMID   18505444. S2CID   205457755.
  47. ↑ Tiku, Patience E.; Nowell, Peter T. (1991). "Selective inhibition of K+-stimulation of Na,K-ATPase by bretylium". British Journal of Pharmacology. 104 (4): 895–900. doi:10.1111/j.1476-5381.1991.tb12523.x. PMC   1908819 . PMID   1667290.
  48. ↑ Shon KJ, Stocker M, Terlau H, Stühmer W, Jacobsen R, Walker C, Grilley M, Watkins M, Hillyard DR, Gray WR, Olivera BM (1998). "kappa-Conotoxin PVIIA is a peptide inhibiting the shaker K+ channel". J. Biol. Chem. 273 (1): 33–38. doi: 10.1074/jbc.273.1.33 . PMID   9417043. S2CID   26009966.
  49. ↑ Roukoz H; Saliba W (January 2007). "Dofetilide: a new class III antiarrhythmic agent". Expert Rev Cardiovasc Ther. 5 (1): 9–19. doi:10.1586/14779072.5.1.9. PMID   17187453. S2CID   11255636.
  50. ↑ Guillemare E, Marion A, Nisato D, Gautier P, “Inhibitory effects of dronedarone on muscarinic K+ current in guinea pig atrial cells,” in Journal of Cardiovascular Pharmacology, 2000 7
  51. ↑ Kim I, Boyle KM, Carrol JL (2005) Postnatal development of E-4031-sensitive potassium current in rat carotid chemoreceptor cells. J Appl Physiol98(4):1469-1477,
  52. ↑ Herrington J, Zhou YP, Bugianesi RM, Dulski PM, Feng Y, Warren VA, Smith MM, Kohler MG, Garsky VM, Sanchez M, Wagner M, Raphaelli K, Banerjee P, Ahaghotu C, Wunderler D, Priest BT, Mehl JT, Garcia ML, McManus OB, Kaczorowski GJ, Slaughter RS (April 2006). "Blockers of the delayed-rectifier potassium current in pancreatic beta-cells enhance glucose-dependent insulin secretion". Diabetes. 55 (4): 1034–42. doi: 10.2337/diabetes.55.04.06.db05-0788 . PMID   16567526.
  53. ↑ Herrington J (February 2007). "Gating modifier peptides as probes of pancreatic beta-cell physiology". Toxicon. 49 (2): 231–8. doi:10.1016/j.toxicon.2006.09.012. PMID   17101164.
  54. ↑ Lebrun, Bruno (1997). "A four-disulphide-bridged toxin, with high affinity towards voltage-gated K+ channels, isolated from Heterometrus spinnifer (Scorpionidae) venom". Biochemical Journal. 328 (Pt 1): 321–327. doi:10.1042/bj3280321. PMC   1218924 . PMID   9359871.
  55. ↑ Murray, K. T. (10 February 1998). "Ibutilide". Circulation. 97 (5): 493–497. doi: 10.1161/01.CIR.97.5.493 . PMID   9490245.
  56. ↑ Huys, I; Olamendi-Portugal, T; Garci-Goméz, BI; Vandenberghe, I (2004). "A subfamily of acidic alpha-K(+) toxins". J Biol Chem. 279 (4): 2781–9. doi: 10.1074/jbc.M311029200 . PMID   14561751.
  57. ↑ B. Hille (1967). "The selective inhibition of delayed potassium currents in nerve by tetraethylammonium ions." J. Gen. Physiol.50 1287-1302.
  58. ↑ C. M. Armstrong (1971). "Interaction of tetraethylammonium ion derivatives with the potassium channels of giant axons." J. Gen. Physiol.58 413-437.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.